Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthijs J Scheltema

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
BJU International|October 7, 2023
Electronic health record and research; happy marriage or early divorce?Matthijs J Scheltema, Bas W G van Rhijn
Nature Reviews. Urology|March 1, 2023
Salvage irreversible electroporation for radio-recurrent prostate cancerMatthijs J Scheltema, Athos Katelaris, Phillip D Stricker
BJU International|November 15, 2019
Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatmentAlexandar Blazevski, Matthijs J Scheltema, Amer Amin, et al.
BJU International|September 9, 2022
Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?Sean Ong, Kenneth Chen, Jeremy Grummet, et al.
European Urology|December 24, 2017
Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive CasesJames E Thompson, Sam Egger, Maret Böhm, et al.
World Journal of Urology|June 4, 2020
Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE)Alexandar Blazevski, Amer Amin, Matthijs J Scheltema, et al.
The Lancet. Diabetes & Endocrinology|September 19, 2016
Clinical relevance of the bile acid receptor TGR5 in metabolismF Samuel van Nierop, Matthijs J Scheltema, Hannah M Eggink, et al.
European Urology Oncology|May 20, 2019
Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective CohortAlexandar Blazevski, Matthijs J Scheltema, Brian Yuen, et al.
BJU International|October 11, 2018
Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlookIlan Gielchinsky, John Chang, Thomas Cusick, et al.
BJU International|December 10, 2022
Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancerMatthijs J Scheltema, Bart Geboers, Alexandar Blazevski, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
BJU International|October 7, 2023
Electronic health record and research; happy marriage or early divorce?Matthijs J Scheltema, Bas W G van Rhijn
Nature Reviews. Urology|March 1, 2023
Salvage irreversible electroporation for radio-recurrent prostate cancerMatthijs J Scheltema, Athos Katelaris, Phillip D Stricker
BJU International|November 15, 2019
Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatmentAlexandar Blazevski, Matthijs J Scheltema, Amer Amin, et al.
BJU International|September 9, 2022
Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?Sean Ong, Kenneth Chen, Jeremy Grummet, et al.
European Urology|December 24, 2017
Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive CasesJames E Thompson, Sam Egger, Maret Böhm, et al.
World Journal of Urology|June 4, 2020
Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE)Alexandar Blazevski, Amer Amin, Matthijs J Scheltema, et al.
The Lancet. Diabetes & Endocrinology|September 19, 2016
Clinical relevance of the bile acid receptor TGR5 in metabolismF Samuel van Nierop, Matthijs J Scheltema, Hannah M Eggink, et al.
European Urology Oncology|May 20, 2019
Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective CohortAlexandar Blazevski, Matthijs J Scheltema, Brian Yuen, et al.
BJU International|October 11, 2018
Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlookIlan Gielchinsky, John Chang, Thomas Cusick, et al.
BJU International|December 10, 2022
Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancerMatthijs J Scheltema, Bart Geboers, Alexandar Blazevski, et al.
Pageof 4